Table 1.
Activity of compounds against FCoV in fcwf-4 cells.
| Compound | Source | Highest concentration tested | CC50 | Inhibition of CPE formation | IC50 |
|---|---|---|---|---|---|
| Nucleoside analogues | |||||
| Acyclovir | GlaxoSmithKline (London, UK) | 888 μM | ≥888 μM | − | NA |
| Idoxuridine | Pharmacy compound | 141.2 μM | ≥141.2 μM | − | NA |
| Ribavirin | Roche (Basel, Switzerland) | 12.8 μM | ≥409.49 μM | − | NA |
| Protease inhibitors | |||||
| Atazanavir | Bristol-Myers Squibb (New York, USA) | 17.75 μM | 48.59 μM | − | NA |
| Indinavir | Merck (Whitehouse station, USA) | 70.237 μM | ≥70.237 μM | − | NA |
| Lopinavir/ritonavir | Abbott Laboratories (Abbott Park, USA) | 3.125 μg/mL | 47.04 μg/mL | − | NA |
| Nelfinavir | Roche (Basel, Switzerland) | 9.41 μM | 11.45 μM | + | 8.19 μM |
| Saquinavir | Roche (Basel, Switzerland) | 4.658 μM | 95.83 μM | − | NA |
| Reverse transcriptase inhibitors | |||||
| Efavirenz | Merck (Whitehouse station, USA) | 9.899 μM | 52.14 μM | − | NA |
| Lamivudine | GlaxoSmithKline (London, UK) | 27.257 μM | ≥27.257 μM | − | NA |
| Lamivudine/zidovudine | GlaxoSmithKline (London, UK) | 12.5 μg/mL | ≥12.5 μg/mL | − | NA |
| Nelvirapine | Boehringer Ingelheim (Ingelheim am Rhein, Germany) | 46.94 μM | ≥46.94 μM | − | NA |
| Stavudine | Bristol-Myers Squibb (New York, USA) | 55.754 μM | ≥55.754 μM | − | NA |
| Other | |||||
| Emodin | Sigma, E7881 (St Louis, USA) | 12.5 μM | 67.41 μM | − | NA |
| Galanthus nivalis agglutinin | Sigma, L8275 (St Louis, USA) | 0.48 nM | ≥1.92 nM | + | 0.0088 nM |
| Promazine | Sigma, P6656 (St Louis, USA) | 100 nM | ≥100 nM | − | NA |
NA: not available.